FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281857937> ?p ?o ?g. }

• W4281857937 abstract "TMPRSS2, a cell surface protease regulated by androgens and commonly upregulated in prostate cancer (PCa), is a necessary component for SARS-CoV-2 viral entry into respiratory epithelial cells. Previous reports suggested a lower risk of SARS-CoV-2 among PCa patients on androgen deprivation therapy (ADT). However, the impact of ADT on severe COVID-19 illness is poorly understood.We performed a multicenter study across 7 US medical centers and evaluated patients with PCa and SARS-CoV-2 detected by polymerase-chain-reaction between March 1, 2020, and May 31, 2020. PCa patients were considered on ADT if they had received appropriate ADT treatment within 6 months of COVID-19 diagnosis. We used multivariable logistic and Cox proportional-hazard regression models for analysis. All statistical tests were 2-sided.We identified 465 PCa patients (median age = 71 years) with a median follow-up of 60 days. Age, body mass index, cardiovascular comorbidity, and PCa clinical disease state adjusted overall survival (hazard ratio [HR] = 1.16, 95% confidence interval [CI] = 0.68 to 1.98, P = .59), hospitalization status (HR = 0.96, 95% CI = 0.52 to 1.77, P = .90), supplemental oxygenation (HR 1.14, 95% CI = 0.66 to 1.99, P = .64), and use of mechanical ventilation (HR = 0.81, 95% CI = 0.25 to 2.66, P = .73) were similar between ADT and non-ADT cohorts. Similarly, the addition of androgen receptor-directed therapy within 30 days of COVID-19 diagnosis to ADT vs ADT alone did not statistically significantly affect overall survival (androgen receptor-directed therapy: HR = 1.27, 95% CI = 0.69 to 2.32, P = .44).In this retrospective cohort of PCa patients, the use of ADT was not demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age 70 years and older was statistically significantly associated with a higher risk of developing severe COVID-19 disease." @default.
• W4281857937 created "2022-06-13" @default.
• W4281857937 creator A5001650260 @default.
• W4281857937 creator A5007663088 @default.
• W4281857937 creator A5008618048 @default.
• W4281857937 creator A5011263550 @default.
• W4281857937 creator A5017288060 @default.
• W4281857937 creator A5018292930 @default.
• W4281857937 creator A5019448536 @default.
• W4281857937 creator A5021731378 @default.
• W4281857937 creator A5024278705 @default.
• W4281857937 creator A5050320394 @default.
• W4281857937 creator A5052102765 @default.
• W4281857937 creator A5056766924 @default.
• W4281857937 creator A5058692226 @default.
• W4281857937 creator A5059178256 @default.
• W4281857937 creator A5061020970 @default.
• W4281857937 creator A5065363382 @default.
• W4281857937 creator A5071318362 @default.
• W4281857937 creator A5077452703 @default.
• W4281857937 creator A5077617529 @default.
• W4281857937 creator A5077678835 @default.
• W4281857937 creator A5080995478 @default.
• W4281857937 creator A5081070547 @default.
• W4281857937 date "2022-05-02" @default.
• W4281857937 modified "2023-10-06" @default.
• W4281857937 title "The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer" @default.
• W4281857937 cites W1614690294 @default.
• W4281857937 cites W2051827271 @default.
• W4281857937 cites W2099045066 @default.
• W4281857937 cites W2101506295 @default.
• W4281857937 cites W2104530249 @default.
• W4281857937 cites W2909787042 @default.
• W4281857937 cites W3008028633 @default.
• W4281857937 cites W3009912996 @default.
• W4281857937 cites W3016535995 @default.
• W4281857937 cites W3023316367 @default.
• W4281857937 cites W3027630905 @default.
• W4281857937 cites W3036807664 @default.
• W4281857937 cites W3037225065 @default.
• W4281857937 cites W3041171695 @default.
• W4281857937 cites W3047144258 @default.
• W4281857937 cites W3084058347 @default.
• W4281857937 cites W3129019794 @default.
• W4281857937 cites W3129052351 @default.
• W4281857937 cites W3211708924 @default.
• W4281857937 cites W4205827212 @default.
• W4281857937 cites W4210642183 @default.
• W4281857937 doi "https://doi.org/10.1093/jncics/pkac035" @default.
• W4281857937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35657341" @default.
• W4281857937 hasPublicationYear "2022" @default.
• W4281857937 type Work @default.
• W4281857937 citedByCount "5" @default.
• W4281857937 countsByYear W42818579372022 @default.
• W4281857937 countsByYear W42818579372023 @default.
• W4281857937 crossrefType "journal-article" @default.
• W4281857937 hasAuthorship W4281857937A5001650260 @default.
• W4281857937 hasAuthorship W4281857937A5007663088 @default.
• W4281857937 hasAuthorship W4281857937A5008618048 @default.
• W4281857937 hasAuthorship W4281857937A5011263550 @default.
• W4281857937 hasAuthorship W4281857937A5017288060 @default.
• W4281857937 hasAuthorship W4281857937A5018292930 @default.
• W4281857937 hasAuthorship W4281857937A5019448536 @default.
• W4281857937 hasAuthorship W4281857937A5021731378 @default.
• W4281857937 hasAuthorship W4281857937A5024278705 @default.
• W4281857937 hasAuthorship W4281857937A5050320394 @default.
• W4281857937 hasAuthorship W4281857937A5052102765 @default.
• W4281857937 hasAuthorship W4281857937A5056766924 @default.
• W4281857937 hasAuthorship W4281857937A5058692226 @default.
• W4281857937 hasAuthorship W4281857937A5059178256 @default.
• W4281857937 hasAuthorship W4281857937A5061020970 @default.
• W4281857937 hasAuthorship W4281857937A5065363382 @default.
• W4281857937 hasAuthorship W4281857937A5071318362 @default.
• W4281857937 hasAuthorship W4281857937A5077452703 @default.
• W4281857937 hasAuthorship W4281857937A5077617529 @default.
• W4281857937 hasAuthorship W4281857937A5077678835 @default.
• W4281857937 hasAuthorship W4281857937A5080995478 @default.
• W4281857937 hasAuthorship W4281857937A5081070547 @default.
• W4281857937 hasBestOaLocation W42818579371 @default.
• W4281857937 hasConcept C121608353 @default.
• W4281857937 hasConcept C126322002 @default.
• W4281857937 hasConcept C143998085 @default.
• W4281857937 hasConcept C151956035 @default.
• W4281857937 hasConcept C207103383 @default.
• W4281857937 hasConcept C2776551883 @default.
• W4281857937 hasConcept C2777899217 @default.
• W4281857937 hasConcept C2778042024 @default.
• W4281857937 hasConcept C2779134260 @default.
• W4281857937 hasConcept C2779159551 @default.
• W4281857937 hasConcept C2780192828 @default.
• W4281857937 hasConcept C3008058167 @default.
• W4281857937 hasConcept C44249647 @default.
• W4281857937 hasConcept C50382708 @default.
• W4281857937 hasConcept C524204448 @default.
• W4281857937 hasConcept C61367390 @default.
• W4281857937 hasConcept C71924100 @default.
• W4281857937 hasConceptScore W4281857937C121608353 @default.
• W4281857937 hasConceptScore W4281857937C126322002 @default.
• W4281857937 hasConceptScore W4281857937C143998085 @default.
• W4281857937 hasConceptScore W4281857937C151956035 @default.

• next